| Hazard Information | Back Directory | [Uses]
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1]. | [in vivo]
Sirtratumab vedotin (ASG15-ME; 0.25-5 mg/kg; i.v.; 2x per week for 2 or 3 weeks or single dose) shows potent antitumor activity in multiple xenograft models in mice[1]. | Animal Model: | SCID mice, RT4 xenograft model[1] | | Dosage: | 5 mg/kg | | Administration: | Intravenous injection, single dose | | Result: | Caused significant inhibition. |
| Animal Model: | SCID mice, AG-B7 and AG-B8 xenograft model[1] | | Dosage: | 0.25 and 0.5 mg/kg | | Administration: | Intravenous injection, 2x per week for 2 or 3 weeks | | Result: | Significantly reduced tumor volume. |
| Animal Model: | SCID mice, the lung xenograft model NCI-H322M[1] | | Dosage: | 3 mg/kg | | Administration: | Intravenous injection, 2x per week for 3 weeks | | Result: | Was able to cause 99% tumor growth inhibition. |
| [References]
[1] Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15(6):1301-10. DOI:10.1158/1535-7163.MCT-15-0570 |
|
| Company Name: |
bioleaper
|
| Tel: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|